MCKESSON CORPORATION |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 586.9 USD | +0.13% |
|
+3.04% | +26.77% |
| 12:18am | Top law firms in US opioid lawsuits to get hundreds of millions in fees | RE |
| Jun. 06 | Mckesson Insider Sold Shares Worth $2,155,761, According to a Recent SEC Filing | MT |
Financials (USD)
| Sales 2025 * | 358B | Sales 2026 * | 388B | Capitalization | 76.29B |
|---|---|---|---|---|---|
| Net income 2025 * | 3.7B | Net income 2026 * | 3.92B | EV / Sales 2025 * | 0.21 x |
| Net cash position 2025 * | 161M | Net cash position 2026 * | 3.01B | EV / Sales 2026 * | 0.19 x |
| P/E ratio 2025 * |
20.1
x | P/E ratio 2026 * |
18.3
x | Employees | 48,000 |
| Yield 2025 * |
0.46% | Yield 2026 * |
0.49% | Free-Float | 46.71% |
More Fundamentals
* Assessed data
More news
Latest transcript on McKesson Corporation
More recommendations
More press releases
More news
| 1 day | +0.13% | ||
| 1 week | +3.04% | ||
| Current month | +3.04% | ||
| 1 month | +7.54% | ||
| 3 months | +11.05% | ||
| 6 months | +28.80% | ||
| Current year | +26.77% |
1 week
565.78
591.80
1 month
543.89591.80
Current year
462.70591.80
1 year
387.28591.80
3 years
184.43591.80
5 years
112.60591.80
10 years
106.11591.80
| Managers | Title | Age | Since |
|---|---|---|---|
Brian Tyler
CEO | Chief Executive Officer | 57 | 11-12-31 |
| Director of Finance/CFO | 55 | 18-01-26 | |
Francisco Fraga
CTO | Chief Tech/Sci/R&D Officer | 51 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Donald Knauss
CHM | Chairman | 73 | 14-10-19 |
Webster Dunbar
BRD | Director/Board Member | 62 | 22-03-31 |
| Director/Board Member | 66 | 22-01-12 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 2.31% | 1,184 M€ | +9.78% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-07 | 586.9 | +0.13% | 541,803 |
| 24-06-06 | 586.1 | +1.12% | 495,518 |
| 24-06-05 | 579.6 | +1.02% | 480,980 |
| 24-06-04 | 573.7 | +0.10% | 488,706 |
| 24-06-03 | 573.2 | +0.63% | 1,055,931 |
Delayed Quote Nyse, June 07, 2024 at 04:00 pm EDT
More quotes
McKesson Corporation specializes in pharmaceutical product distribution. The group also offers technological services to healthcare companies. Net sales break down by activity as follows:
- distribution of pharmaceutical products (87%);
- distribution of medical and surgical products (4%);
- other (1.6%): primarily technology services and software sales.
The remaining net sales (7.4%) are from international activities.
Sector
Pharmaceuticals
Calendar
2024-07-30
- Q1 2025 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
18
Last Close Price
586.9
USD
Average target price
589.5
USD
Spread / Average Target
+0.45%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +26.77% | 76.29B | |
| -2.27% | 23.99B | |
| +10.27% | 9.01B | |
| +12.25% | 8.67B | |
| -24.34% | 7.58B | |
| +12.70% | 5.18B | |
| +2.89% | 4.16B | |
| -4.96% | 3.98B | |
| -1.36% | 3.63B | |
| +20.13% | 3.58B |
- Stock Market
- Equities
- MCK Stock
